NCT01698736View on ClinicalTrials.gov

ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Immunology
Interventions
DEVICE

Membrane filtration

Membrane filtration (Polysulfone)

DEVICE

Semiselective IA

Semiselective immunoadsorption (GAM peptide adsorber)

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
collaborator

Fresenius Medical Care Deutschland GmbH

INDUSTRY

lead

Medical University of Vienna

OTHER

NCT01698736 - ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration | Biotech Hunter | Biotech Hunter